Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 2500 participants.
Also called NCT07232030
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 2,500 participants
- Sponsor
- CVRx, Inc.
- Registry
-
NCT07232030
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States
- Registry status
- Recruiting
Technical summary
Registry record NCT07232030. Randomized; no masking; primary purpose treatment. Start 2026-04-24 (actual); primary completion 2033-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure
- Acronym
- BENEFIT-HF
- Condition
- Heart Failure
- Condition
- Heart Failure NYHA Class II
- Condition
- Heart Failure NYHA Class III
- Intervention (Device)
- Barostim System
- Intervention (Other)
- Usual care medical management
- Lead sponsor
- CVRx, Inc.
Record details
- Record id
cardio:ct-nct07232030- Content hash
7bbe2af4113ecc9fa2a392dcf3a35d1adec557265e6a28c69ee597b28e8f5304